Prosecution Insights
Prosecution Insights
7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 2 | 44.3% | +32.1% |
| GOLDBERG, JEANINE ANNE | 1 | 45.9% | +40.9% |
| MCKOY, QUINCY ANDRE | 1 | 70.0% | +39.5% |
| CHO, DAVID H | 1 | 37.5% | +73.5% |
| HUANG, GIGI GEORGIANA | 1 | 31.7% | +30.6% |
| PECKHAM, RICHARD GRANT | 1 | 67.2% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18473540 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | MCKOY, QUINCY ANDRE | 73d overdue |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | CHO, DAVID H | 31d overdue |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 5d overdue |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 2d overdue |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18473540 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | MCKOY, QUINCY ANDRE | 73d overdue |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | CHO, DAVID H | 31d overdue |
| 16310566 | Active Alpha-5-Beta-1 Integrin As A Biomarker For Enhancing Tumor Treatment Efficacy | DENT, ALANA HARRIS | 9d overdue |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 5d overdue |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 2d overdue |
| 17055722 | Urinary DNA Detection For Urothelial Cancer | DENT, ALANA HARRIS | 20d |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1682 | 1 |
| 1626 | 1 |
| 1693 | 1 |
| 1613 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | 1682 | §101§102§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18473540 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | MCKOY, QUINCY ANDRE | 1626 | §102§112 | Non-Final OA | 73d overdue | Pending | Sep 25, 2023 |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | CHO, DAVID H | 1693 | §103§112Other | Non-Final OA | 31d overdue | Pending | Jul 07, 2022 |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 1613 | §103§112 | Non-Final OA | 5d overdue | Pending | Nov 22, 2021 |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 1627 | §103§112 | Final Rejection | 2d overdue | Pending | Nov 16, 2021 |
| 17055722 | Urinary DNA Detection For Urothelial Cancer | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 20d | Pending | Nov 16, 2020 |
| 16310566 | Active Alpha-5-Beta-1 Integrin As A Biomarker For Enhancing Tumor Treatment Efficacy | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 9d overdue | Pending | Dec 17, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial